These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1948095)

  • 21. Pharmacokinetic and biological activities of dermatan sulfate (Mediolanum MF701) in healthy human volunteers.
    Dawes J; Hodson BA; MacGregor IR; Pepper DS; Prowse CV
    Ann N Y Acad Sci; 1989; 556():292-303. PubMed ID: 2735660
    [No Abstract]   [Full Text] [Related]  

  • 22. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli.
    Van Ryn-McKenna J; Gray E; Weber E; Ofosu FA; Buchanan MR
    Thromb Haemost; 1989 Feb; 61(1):7-9. PubMed ID: 2473537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig.
    Eriksson M; Larsson A; Saldeen T; Mattsson C
    Thromb Haemost; 1998 Dec; 80(6):1022-6. PubMed ID: 9869178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological studies on the antithrombotic action of hirudin in experimental animals.
    Markwardt F; Hauptmann J; Nowak G; Klessen C; Walsmann P
    Thromb Haemost; 1982 Jun; 47(3):226-9. PubMed ID: 7112494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
    Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
    Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative.
    Harenberg J; Casu B; Guerrini M; Malsch R; Naggi A; Piazolo L; Torri G
    Semin Thromb Hemost; 2002 Aug; 28(4):343-54. PubMed ID: 12244481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects.
    Cipriani TR; Gracher AH; de Souza LM; Fonseca RJ; Belmiro CL; Gorin PA; Sassaki GL; Iacomini M
    Thromb Haemost; 2009 May; 101(5):860-6. PubMed ID: 19404539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
    Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
    Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of heparin and of dermatan sulfate: clinical implications.
    Boneu B; Caranobe C; Salvin S; Dol F; Sié P
    Adv Exp Med Biol; 1992; 313():237-47. PubMed ID: 1332440
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
    Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A
    J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
    Eriksson BI; Carlsson S; Halvarsson M; Risberg B; Mattsson C
    Thromb Haemost; 1997 Nov; 78(5):1404-7. PubMed ID: 9408027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
    Petitou M; Duchaussoy P; Jaurand G; Gourvenec F; Lederman I; Strassel JM; Bârzu T; Crépon B; Hérault JP; Lormeau JC; Bernat A; Herbert JM
    J Med Chem; 1997 May; 40(11):1600-7. PubMed ID: 9171870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
    Merton RE; Thomas DP
    Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
    Kaiser B; Hauptmann J; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a novel dermatan sulfate with high antithrombin activity from ray skin (Raja radula).
    Ben Mansour M; Dhahri M; Bertholon I; Ollivier V; Bataille I; Ajzenberg N; Hassine M; Jandrot-Perrus M; Chaubet F; Maaroufi RM
    Thromb Res; 2009 Apr; 123(6):887-94. PubMed ID: 19019412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
    Tucker TJ; Brady SF; Lumma WC; Lewis SD; Gardell SJ; Naylor-Olsen AM; Yan Y; Sisko JT; Stauffer KJ; Lucas BJ; Lynch JJ; Cook JJ; Stranieri MT; Holahan MA; Lyle EA; Baskin EP; Chen IW; Dancheck KB; Krueger JA; Cooper CM; Vacca JP
    J Med Chem; 1998 Aug; 41(17):3210-9. PubMed ID: 9703466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.